key: cord-0289739-6y16mczx
authors: Ma, Hang; Guo, Yingying; Tang, Haoneng; Tseng, Chien-Te K.; Wang, Lei; Zong, Huifang; Wang, Zhenyu; He, Yang; Chang, Yunsong; Wang, Shusheng; Huang, Haiqiu; Ke, Yong; Yuan, Yunsheng; Wu, Mingyuan; Zhang, Yuanyuan; Drelich, Aleksandra; Kempaiah, Kempaiah Rayavara; Peng, Bi-Hung; Wang, Ailin; Yang, Kaiyong; Yin, Haiyang; Liu, Junjun; Yue, Yali; Xu, Wenbo; Zhu, Shuangli; Ji, Tianjiao; Zhang, Xiaoju; Wang, Ziqi; Li, Gang; Liu, Guangchun; Song, Jingjing; Mu, Lingling; Xiang, ZongShang; Song, Zhangyi; Chen, Hua; Bian, Yanlin; Zhang, Baohong; Chen, Hui; Zhang, Jiawei; Liao, Yunji; Zhang, Li; Yang, Li; Chen, Yi; Gilly, John; Xiao, Xiaodong; Han, Lei; Jiang, Hua; Xie, Yueqing; Zhou, Qiang; Zhu, Jianwei
title: Broad ultra-potent neutralization of SARS-CoV-2 variants by monoclonal antibodies specific to the tip of RBD
date: 2021-09-25
journal: bioRxiv
DOI: 10.1101/2021.09.24.461616
sha: ad845256b244bffbe75ffecc9278c766fd86002c
doc_id: 289739
cord_uid: 6y16mczx

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) continue to wreak havoc across the globe. Higher transmissibility and immunologic resistance of VOCs bring unprecedented challenges to epidemic extinguishment. Here we describe a monoclonal antibody, 2G1, that neutralizes all current VOCs and has surprising tolerance to mutations adjacent to or within its interaction epitope. Cryo-electron microscopy structure showed that 2G1 bound to the tip of receptor binding domain (RBD) of spike protein with small contact interface but strong hydrophobic effect, which resulted in nanomolar to sub-nanomolar affinities to spike proteins. The epitope of 2G1 on RBD partially overlaps with ACE2 interface, which gives 2G1 ability to block interaction between RBD and ACE2. The narrow binding epitope but high affinity bestow outstanding therapeutic efficacy upon 2G1 that neutralized VOCs with sub-nanomolar IC50 in vitro. In SARS-CoV-2 and Beta- and Delta-variant-challenged transgenic mice and rhesus macaque models, 2G1 protected animals from clinical illness and eliminated viral burden, without serious impact to animal safety. Mutagenesis experiments suggest that 2G1 could be potentially capable of dealing with emerging SARS-CoV-2 variants in future. This report characterized the therapeutic antibodies specific to the tip of spike against SARS-CoV-2 variants and highlights the potential clinical applications as well as for developing vaccine and cocktail therapy.

therapeutic efficacy upon 2G1 that neutralized VOCs with sub-nanomolar IC50 in vitro. In 56 SARS-CoV-2 and Beta-and Delta-variant-challenged transgenic mice and rhesus 57 macaque models, 2G1 protected animals from clinical illness and eliminated viral burden, 58

without serious impact to animal safety. Mutagenesis experiments suggest that 2G1 could 59 be potentially capable of dealing with emerging SARS-CoV-2 variants in future. This report 60 characterized the therapeutic antibodies specific to the tip of spike against SARS-CoV-2 61

variants and highlights the potential clinical applications as well as for developing vaccine 62

and cocktail therapy .  63  64  65  66  67  68  69  70  71  72  73  74  75  76  77  78  79  80  81  82  83  84  85  86  87  88  Introduction  89 Since the first Coronavirus Disease 2019 case was diagnosed at the end of 90 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused 91 more than 200 million confirmed infections and 4.5 million deaths in the following eighteen 92 months, with no sign of stopping (https://ourworldindata.org/coronavirus) 1-6 . The hope-93 placed distribution of vaccines once appeared effectively controlling the virus spread. 94

However, the antigenic evolution of SARS-CoV-2, especially in the spike (S) protein 95 associated with receptor binding, alters the viral immunogenicity facilitating the virus's 96 immune escape and crossing transmission barriers 7,8 . 97

Receptor binding domain (RBD) on the S protein is a determinant that mediates the binding 98

of SARS-CoV-2 to the angiotensin-converting enzyme 2 (ACE2). Neutralizing antibodies 99 targeting RBD were proved to be effective 9-11 . Correspondingly, substitutions on RBD may 100 reduce neutralizing efficacy [12] [13] [14] . Several variants, listed as Variant of Concern (VOC), 101 featured with RBD substitutions and non-RBD mutations showed to have higher 102

transmissibility and led to more severe illness 15-17 , which has been causing great global 103 dissemination concern. SARS-CoV-2 B.1.1.7 (Alpha) was first identified in United Kingdom 104

in late summer of 2020 and rapidly became the dominant variant. This variant has nine 105 mutations in the S protein, one of which is N501Y in RBD 18 . Alpha variant possesses a 106 comparative transmission advantage, with a reproductive number 50% to 100% higher 107 than other non-VOC lineages 1 . Vaccine-elicited neutralizing antibody responses were 108

shown to be at risk of being desensitized by Alpha 19 Similarly, Gamma variant notably reduced susceptibility to antibody treatment and vaccine 116 protection 23,24 . SARS-CoV-2 B.1.617.2 (Delta) was first reported in India and quickly 117 spread globally in the first half of 2021. This strain has more than ten S protein mutations 118 and two of them, L452R and T478K, are in RBD. Delta variant exhibits more extensive 119 immunologic resistance than Alpha, escaping from many S protein antibodies targeting 120 RBD and non-RBD epitopes 25, 26 . Individuals who recovered from Beta and Gamma 121

variants are more susceptible to be infected with Delta 27 . In addition to these VOCs, 122 potential outbreaks of several variants have raised public concern, such as the recently 123

rapidly spreading variant C.37 (Lambda) 28 and the new variant B.1.621 (Mu) 29 . The 124 emergence of these variants, even possible hybrid variants, raises the risk of 125

compromising the therapeutic effectiveness of vaccines and neutralizing antibodies that 126

were previously developed 30,31 . 127

Here we report our efforts on discovering neutralizing antibodies that provide extensive 128 protection against the variants with global impact, especially the VOCs. We isolated RBD 129 positive single B cells from convalescent individuals and cloned monoclonal antibodies 130 (mAbs) within. After a series of programmed screening, several antibodies with remarkable 131

neutralizing effect were panned out from the candidates (Fig. 1a) . One of these antibodies, 132 designated as 2G1, efficiently neutralized all VOCs including widely spread Alpha, Beta, 133 Gamma, Delta variants and Cluster 5, a variant with Y453F substitution once caused public 134 concern due to the zoonotic characteristics. The antibody 2G1 was subsequently fully 135 characterized physic-chemically and biologically, as well as evaluated in potential in clinical 136

applications.

Results

Molecule discovery of 2G1 140

We collected blood samples from 20 convalescent individuals who were infected by SARS-141

CoV-2 in February 2020. Peripheral blood mononuclear cells were enriched and sorted 142

with fluorescently labeled recombinant SARS-CoV-2 RBD (WA1/2020) protein (Fig. 1b) . 143

Over 1200 B cells were isolated and more than 500 pairs of IgG antibody genes were 144

cloned by single-cell PCR. Of which, 375 are kappa subtype and 174 are lambda subtype 145 (Fig. 1c) . 143 RBD binders were obtained after the ELISA-based preliminary screening 146 (Fig. 1d ). In the following pseudovirus-based screening, three molecules, including 2G1, 147

displayed ultra-potent neutralization with IC50 less than 0.01 μg/mL (Fig. 1e ). Antibody 2G1 148 stood out from these candidates after further investigation despite the binding and ACE2 149 blocking abilities were not remarkable (Supplementary information, Fig. S1a -b). In the 150 germline analysis of 33 candidates, 23 heavy chains were from IGHV3 and 18 light chains 151

were from IGKV1 (Supplementary information, Fig. S2 ). Six heavy chains, including 2G1, 152

were from IGHV3-53, which was reported having short complementarity-determining 153 region and with minimal affinity but high efficacy 32 . 154 WA1/2020 RBD-mFc and S trimer proteins and pseudovirus were employed to further 155 confirm the antigen-binding and neutralizing ability of 2G1. Antibody 2G1 bound to RBD-156 mFc and S trimer with EC50 of 0.016 μg/mL and 0.135 μg/mL ( Fig. 2a- 15.30 nM, respectively (Fig. 3c) . The dissociation rate of 2G1/Delta (Kd = 4.27 × 10 -2 s -1 ) 178

was increased as compared with WA1/2020 (Kd = 1.05 × 10 -3 s -1 ), which leads to the 179 decrease in affinity.

In pseudovirus neutralization assays, we found that antibody 2G1 robustly neutralized all 181 pseudoviruses, including D614G, Alpha, Beta, Gamma, Delta, and Cluster 5 variants ( Fig.  182 4a-g, Supplementary information, Fig. S3 ) with low IC50, especially 0.0005 μg/mL against 183

Gamma and 0.0002 μg/mL against Cluster 5. Live SARS-CoV-2 neutralization assay 184 results were consistent with those from experiments using pseudoviruses. Antibody 2G1 185 neutralized WA1/2020 live virus with IC50 of 0.0240 μg/mL (Fig. 4h) while it was more 186

inclined to neutralize Alpha, Beta, and Gamma live virus, with IC50 decrease about 1.7-fold 187 (0.0138 μg/mL), 5.2-fold (0.0046 μg/mL), and 3.0-fold (0.0079 μg/mL). In this assay, 2G1 188

had the same neutralizing activity (IC50 = 0.0240 μg/mL) against Delta and WA1/2020.

In vivo protection in animal models 191

To evaluate in vivo antiviral efficacy of 2G1 against SARS-CoV-2 challenge, we performed 192 viral clearance assay employing both ACE2 transgenic mouse and rhesus macaque 193 models. In the transgenic mouse study, animals were challenged with high copies of 100 194

times of half lethal dose (LD50) of SARS-CoV-2 WA1/2020, Beta, or Delta at day 0, followed 195 by three different 2G1 dose treatments (20, 6.7 or 2.2 mg/kg) or vehicle injection (PBS).

Four days post infection (dpi), four mice in each group including vehicle and differentially 197 treated groups were euthanized, and lungs and brains were collected for the titration of 198 viral load (Fig. 5a ). Mice treated with vehicle developed an acute wasting syndrome and 199

quickly met the designed endpoint at 5 dpi. In contrast, WA1/2020 and Beta virus-infected 200 mice that received 20, 6.7 or 2.2 mg/kg treatments survived without losing any weight or 201 revealing any obvious signs of illness throughout the study (Fig. 5b-d) . Delta virus-infected 202 mice in the 20 mg/kg group all survived throughout the trial period and had a good clinical 203 wellbeing score. In the same study, 55.6% mice in the 6.7 mg/kg group and 10% mice in 204 the 2.2 mg/kg group recovered back to healthy physiological condition ( Fig. 5b -d) from the 205 virus challenge. The results indicated that at the range of 6.7 -20 mg/kg 2G1 antibody 206 treatment was effective for animals to recover from the viral infection. 207

In the study of rhesus macaque animal model (Fig. 6a) , the animals were infected with 10 5 208 TCID50 of SARS-CoV-2 (2019-nCoV-WIV04) per animal and randomly divided into control 209 (vehicle injection), low-dose (10 mg/kg of 2G1), and high-dose (50 mg/kg of 2G1) groups, 210

with one male and one female in each group. Drugs were intravenously given 24 h post 211

infection. All animals in the two therapy groups had a high viral load of 10 6 copies/mL in 212 the throat swab at 1 dpi. After the drug injection, the viral titer was gradually decreased. 213

The throat virus was cleared at 3 dpi in one of the high-dose animals and at 4 dpi in the 214 remaining treated animals (Fig. 6b ). One animal in the control group had an elevated viral 215 titer in the anal swab at 5 dpi, but no animals in the antibody treated groups showed this 216 trend until 7 dpi (Fig. 6c ). In addition, we checked the viral distribution in lung, trachea, and 217 bronchus tissues. The virus was detectable in most areas of the lungs, in the tracheas, and 218 bronchi of the control animals. In the group treated with high-dose of the antibody, the virus 219 was present in right-middle, left-middle, and left-lower of the lungs, as well as left-bronchi. 220

In the low-dose group, the virus was only found in tracheas (Fig. 6d) Cryo-EM structure of the complex between 2G1 and SARS-CoV-2 S protein 239

To investigate the binding mode of antibody 2G1 on S trimer, we solved the cryo-electron 240 microscopy (cryo-EM) structure of 2G1 in complex with S trimer at 2.7 Å resolution ( Fig.  241 7a, Supplementary information, Fig. S6-7) . Yet, the cryo-EM map density on the interface 242 between RBD and 2G1 were smeared. So, we performed local refinement 243

and improved the antibody-antigen interface resolution to 3.2Å, enabling reliable analysis 244 of the interactions between the RBD and 2G1 (Fig. 7b ). In the S/2G1 complex, three solved 245

Fabs bound to trimeric S with all RBDs in the "down" position and the S protein in a locked 246 conformation 33,34 (Fig. 7a ). There is an additional density in RBD domain of the structure, 247

which was reported as free fatty acid linoleic acid (LA) in a locked conformation 33 . 248

For detailed analysis of the interface, antibody 2G1 binds to tip area of RBD of S trimer, 249

overlapping with the ACE2 binding site on RBD and offset from the major mutational 250 hotspots in VOCs. The heavy chain of 2G1 interacts with RBD mainly through three 251 complementarity-determining regions, named CDRH1 (residues 30 to 35), CDRH2 252

(residues 50 to 65), and CDRH3 (residues 98 to 111). The light chain of 2G1 participates 253 interaction mainly through two CDRs, CDRL1 (residues 23 to 36) and CDRL3 (residues 91 254 to 100) ( Fig. 7b -e). The interface between RBD and 2G1 is stabilized by an extensive 255 hydrophobic interaction network. Phe486 on the RBD top loop interacts with Tyr33, Tyr52 256 on heavy chain and Tyr34, Tyr93, Trp99 on light chain through hydrophobic and/or - 257

interactions simultaneously (Fig. 7c ). CDRH1 and CDRH3 of the 2G1 heavy chain were 258 positioned above the LA binding pocket in the adjacent RBD' (Fig. 7b and 7e ). We further 259 compared 2G1 with three antibodies (S2E12, B1-182.1 and REGN10933), which have 260 similar patterns of epitope ( Fig. 8a-c) . Structural comparison reveals that the epitope for 261

2G1 partially overlaps with these three antibodies (S2E12, B1-182.1 and REGN10933), 262 but they have different binding directions (Fig. 8b) . Besides, 2G1 has a relative narrow 263

binding epitope which may result less probability of losing neutralizing activity due to viral 264 mutagenesis (Fig. 8c) .

Potential escape risk evaluation 267

To address the potential virus escape issue, we collected the high-frequency mutation sites 268 near the 2G1 binding epitope from GISAID database as of August 2021 (Fig. 9a) , and 269

constructed a series of S protein sequences containing these mutations. The change in 270 binding ability of 2G1 was reflected by the normalized mean fluorescent intensity (MFI) 271

relative to the wild-type S protein in flow cytometry. Mutants 484K, 477N/484Q/490S, and 272

477R/478K/484K distinctly reduced 2G1 binding (Fig. 9b ). Mutants 477N/490S, 273 477R/490S, 478K/484Q, and 484K/490S remarkably enhanced 2G1 binding (Fig. 9b) . The 274

484K substitution is featured in variants Beta and Gamma. Although 484K alone leads to 275 a decreased binding ability of 2G1, trimeric S harbor all mutation sites only slightly 276

influenced the affinity of 2G1 (Fig. 3c) . The 484K substitution leads to the loss of salt bridge 277

between Glu484 and ACE2 Lys31, resulting in the reduced affinity of ACE2 35 . It may be 278 one of the reasons why the activity of 2G1 even slightly improved in neutralizing Beta and 279

Gamma mutants. Another substitution in residue 484 with Gln (484Q) only slightly 280

weakened the binding of 2G1 (Fig. 9b ). SARS-CoV-2 Delta variant possesses the T478K 281 substitution, which is a contact residue with 2G1. The single point mutation with T478K has 282 mildly decreased the 2G1 binding ( Fig. 9b) , which is consistent with the SPR data. 283

We also directly mutated the key interacting residues between RBD and 2G1 by alanine 284

substitution, though they are not high-frequency mutation sites. Only moderate decline in 285 2G1 interaction was found in several mutations, including 486A, 489A, 477A/487A, and 286

477A/489A (Fig. 9c) . These results suggest that 2G1 could potentially be effective against 287

future SARS-CoV-2 variants. 288 289

SARS-CoV-2 has no sign of stopping its transmission since the outbreak, and the 291 emergence of variants with increased transmissibility and capability of surveillance escape 292 has assisted its continued existence. Recently, the variant Delta has become an intensively 293

concerned strain due to its unparalleled transmissibility, which is embodied in the 1000 294

times higher viral load than the ancestral strain of SARS-CoV-2 6,36 . The high-frequency 295 mutation nature of SARS-CoV-2 necessitates the development of therapies with 296 breadth 37,38 . We screened antibodies with broad spectrum of neutralizing effects from 297 convalescent subjects. One of which, 2G1, showed excellent and extensive neutralization 298

to both ancestral SARS-CoV-2 WA1/2020 and VOCs at sub-nanomolar IC50 level. In the in 299 vivo study, transgenic mice infected by the WA1/2020-and Beta-were cured by antibody 300 2G1 at a dose as low as 2.2 mg/kg, as well as fully protected from Delta infection in the 301 range from 6.7 to 20 mg/kg, even when animals were challenged with 100 times LD50 of 302 viral load. These results indicate that 2G1 is a potent therapeutic antibody against the 303 broad spectrum of variants currently being concerned. 304

The cryo-EM structure of 2G1 in complex with the S protein revealed that 2G1 binds to the 305 tip of S trimer through small interface but strong hydrophobic effect. The strong 306 hydrophobic effect provides high affinity for 2G1, and the KD of interaction with S trimers of 307 SARS-CoV-2 and VOCs ranges from 0.86 nM to 15.3 nM. SARS-CoV-2 variants Beta and 308 Mu is also seen in Beta and Gamma. In view of the good binding and neutralization of 2G1 328

against Beta and Gamma, we believe that 2G1 will likely be comparatively effective against 329

Mu. In addition, we directly mutated the amino acid residues adjacent to the epitope on 330 RBD by 2G1, as well as several residues that directly interact with 2G1, and found that 331 only few mutation groups may cause a significant weakening of the 2G1 binding ability.

Collectively, the model of 2G1 binding to the tip of S trimer provides a good reference for 333

developing vaccines and optimizing a better combination therapy. 334

The neutralizing antibody 2G1 has been manufactured under cGMP to support the 335

Investigational New Drug application. We would believe that antibody treatment with 2G1 336 will bring clinical benefit to COVID-19 patients. 337 338

Blood samples were obtained from patients who were recovered from COVID-19 for 10 341 weeks and had a negative nucleic acid test. Samples with serum antibody titer over 1 × 342 10 6 were chosen for the peripheral blood mononuclear cells (PBMCs) separation using 343

Ficoll density gradient centrifugation method. B cells were enriched applying a human B 344

Cell Isolation Kit (Stemcell). Afterwards, B cells were then stained with APC-Alex700 345 labeled anti-CD19 (BD), BV421 labeled anti-CD27 (BD), BV510 labeled anti-IgG (BD), 346

Biotin labeled RBD (Sino Biological), PE labeled streptavidin (ThermoFisher) and 7AAD 347

(BD) Single memory B cells with potential SARS-CoV-2 antibody secretion were sorted out 348 by gating 7AAD -, CD19 + , CD27 + , IgG + , and RBD + using a BD Aria III cell sorter with 349

fluorescence-activated cell sorting modules. B cells were suspended into lysis buffer and 350 quickly frozen. B cell mRNA was subsequently converted to cDNA by SuperScript III 351

Reverse Transcriptase (Invitrogen) and V gene were rescued by PCR. to infect HEK-293T cells under selection pressure of 10 μg/mL puromycin (Beyotime 377

Biotechnology). The transfection efficiency was examined by flow cytometry using S1-mFc 378 recombinant protein (Sino Biological) as primary antibody and FITC-AffiniPure Goat Anti-379

Mouse IgG (Jackson) as secondary antibody. The resulting bulk transfected population 380 was sorted on a BD FACSJazz Cell Sorter (BD) with the BD FACS™ Sortware. Cells with 381

top 1% fluorescence intensity were retained and expanded for subsequent use. 382 383

The coding sequence for full-length wild-type S protein (GenBank: QHD43416.1) from 385

Met1 to Thr1273 was inserted into plasmid pHIV-puro1.0, followed by an internal ribosome 386 entry site (IRES) and puromycin resistance gene. The lentiviruses were generated using 387 the HEK-293T packaging system as mentioned above. 500 μL of filtered lentivirus 388 supernatant was added in a 24-well plate with Jurkat cells (ATCC). After cell expansion 389

and selection with 10 μg/mL puromycin for one week, the positive S expression was 390 confirmed by flow cytometry.

Antigen-binding ELISA 393

Enzyme-linked immunosorbent assays (ELISA) were applied to study the binding ability of 394 antibodies with SARS-CoV-2 RBDs (Sino Biological) and S trimers (AcroBiosystems).

Antigens were diluted with ELISA Coating Buffer (Solarbio) to 1.0 μg/mL and immobilized 396 other SARS-CoV-2 RBD specific antibodies were used as a positive control to validate data 445 collection in different panels of screening. Medium containing equal amount of 446 pseudoviruses but no antibodies was used as blank control. The culture medium of ACE2-447

293T cells was removed and then replaced by the antibody-pseudovirus mixture. All 448 operations were conducted in the BSL-2 lab in Shanghai Jiao Tong University. After an 449

additional 48 h incubation, the luminescence of each well was measured using a ONE-450

Glo™ Luciferase Assay System (Promega) in the Infinite M200 Pro NanoQuant (TECAN). 451

The acquired luminescence units were normalized to those of blank control wells. Dose-452 dependent neutralization curves were fitted using a four-parameter nonlinear regression in 453

GraphPad Prism Version 9.0.0. Mice were clinically observed at least once daily and scored based on a 1 to 4 grading 489 system that describes the clinical wellbeing. In the standardized 1 to 4 grading system, 490 score 1 is healthy; Score 2 is with ruffled fur and lethargic; Score 3 is with additional clinical 491 sign such as hunched posture, orbital tightening, increased respiratory rate, and/or > 15% 492 weight loss; Score 4 is showing dyspnea and/or cyanosis, reluctance to move when 493 stimulated, or ≥ 20% weight loss that need immediate euthanasia. Four mice in each group 494

were euthanized at 4 days post infection for assessing viral loads and histopathology of 495 lung and brain. The remaining 10 mice were continue monitored for morbidity and mortality 496

for up to 12 days post infection.

Rhesus macaque protection 499

Rhesus macaques at six to seven years old were purchased from Hubei Tianqin 500

Biotechnology Co., Ltd. All animal procedures and operations were approved by the ethical 501 committee of Wuhan Institute of Virology, Chinese Academy of Sciences. SARS-CoV-2 502 strain 2019-nCoV-WIV04 (GISAID number: EPI_ISI_402124) was isolated from the 503 bronchoalveolar lavage fluid of a patient who was infected COVID-19 in Wuhan in 504

December 2019. Rhesus macaques were randomly divided into control group, low-dose 505 (10 mg/kg of 2G1) and high-dose (50 mg/kg of 2G1) groups with one male and one female 506 in each. Animals were endotracheally infected with 4 mL of 1 × 10 5 TCID50 virus. Antibody 507 2G1 and PBS were intravenously given 24 h after infection. Rhesus macaques were 508 monitored for disease-related changes during the period. Body weight and temperature 509

were measured every day, and throat swab and anal swab samples were collected for virus 510

titrating. Animals were euthanized at 7 dpi and tissue samples were collected for virus 511

examining. Viral RNA was extracted using the QIAamp Viral RNA Mini Kit (Qiagen). A one-512 step real-time quantitative PCR was used to quantify the viral RNA according to the 513 supplier's instructions (HiScript® II One Step qRT-PCR SYBR® Green Kit, Vazyme Biotech 514

Co., Ltd) together with primers for the RBD gene (RBD-qF1: 5'-CAATGGTTAAGGCAGG-515 3'; RBD-qR1: 5'-CTCAAGGTCTGGATCACG-3').

Antibody-Dependent Cellular Phagocytosis (ADCP) 518

In ADCP experiment, CD14 + monocytes (Allcells) were cultured and differentiated for 7 519 days to obtain macrophage cells. Macrophages were labeled with violet dye 520 (ThermoFisher), and Jurkat cells with stable SARS-CoV-2 S expression were labeled with 521 CFSE dye (ThermoFisher and 28 d after injection. Serum 2G1 concentration was quantified using ELISA. Briefly, 531

Mouse Anti-human IgG Lambda (SouthBiotech) at 2 μg/mL was coated in ELISA plates. 532

Serum samples and antibody 2G1 control were added into the plates and incubated for 1 533 h. After washing, a Goat Anti-human Fc HRP (Sigma) was used as secondary antibody 534

with 1:6000 dilutions. After the chromogenic reaction by the HRP substrate (Solarbio), the 535 plates were read at 450 nm. 536

Crlj:CD1(ICR) mice were randomly divided into control (PBS), 15 mg/kg, 30 mg/kg, and 60 537 mg/kg groups for testing the in vivo toxicity of 2G1, with three males and three females 538 each group. Body weight was tracked every two days. Blood samples were collected 14 539 days after administration and mice were subsequently euthanized for tissue damage 540

detection. Blood indicators including white blood cell count, red blood cell count, 541

hemoglobin, and platelets were measured in multiple automated hematology analyzer 542

(Sysmex XT-2000iV). Pathological changes of hearts, livers, spleens, lungs and kidneys 543

were examined by hematoxylin-eosin (HE) staining.

Expression and purification of S protein 546

The prefusion S extracellular domain (1-1208 a.a) (Genbank ID: QHD43416.1) was cloned 547

into the pCAG vector (Invitrogen) with six proline substitutions at residues 817, 892, 899, 548 942, 986 and 987 39 , a "GSAS" substitution (instead of "RRAR") at residues 682 to 685 and 549 a C-terminal T4 fibritin trimerization motif followed by one Flag tag. 550

This recombinant S protein was overexpressed using the HEK 293F mammalian cells 551

(Invitrogen) at 37℃ under 5% CO2 in a Multitron-Pro shaker (Infors, 130 rpm). For secreted 552

S protein production, about 1.5 mg of the plasmid was premixed with 3 mg of 553 polyethylenimines (PEIs) (Polysciences) in 50 mL of fresh medium for 15 mins before 554 adding to cell culture, and transiently transfected into the cells, when the cell density 555 reached 2.0 ×10 6 cells/mL. Cells were removed by centrifugation at 4000×g for 15 mins 556 and cell culture supernatant was collected sixty hours after transfection. The secreted S 557 proteins were purified by anti-FLAG M2 affinity resin (Sigma Aldrich). After loading two 558 times, the anti-FLAG M2 resin was washed with the wash buffer containing 25 mM Tris (pH 559 8.0), 150 mM NaCl. The protein was eluted with the wash buffer plus 0.2 mg/mL flag 560

peptide. The eluent was then concentrated and subjected to gel filtration chromatography 561 (Superose 6 Increase 10/300 GL, GE Healthcare) in buffer containing 25 mM Tris (pH 8.0), 562 150 mM NaCl. The peak fractions were collected and concentrated to incubate with mAb. 563

The purified S protein was mixed with the 2G1 at a molar ratio of about 1:5 for one hour, 564

respectively. Then the mixture was subjected to gel filtration chromatography (Superose 6 565

Increase 10/300 GL, GE Healthcare) in buffer containing 25 mM Tris (pH 8.0), 150 mM 566

NaCl. The peak fractions were collected for EM analysis. 567 568

Cryo-EM sample preparation, data collection and data processing 569

The peak fractions of complex were concentrated to about 2.5 mg/mL and applied to the 570 grids. Aliquots (3.3 μL) of the S/2G1 complex were placed on glow-discharged holey 571 carbon grids (Quantifoil Au R1.2/1.3). The grids were blotted for 2.5 s or 3.0 s and flash-572 frozen in liquid ethane cooled by liquid nitrogen with Vitrobot (Mark IV, ThermoFisher). The 573 prepared grids were transferred to a Titan Krios operating at 300 kV equipped with Gatan 574 K3 detector and GIF Quantum energy filter. Movie stacks were automatically collected 575

using AutoEMation 40 , with a slit width of 20 eV on the energy filter and a defocus range 576 from -1.2 µm to -2.2 µm in super-resolution mode at a nominal magnification of 81,000×. 577

Each stack was exposed for 2.56 s with an exposure time of 0.08 s per frame, resulting in 578 a total of 32 frames per stack. The total dose rate was approximately 50 e -/Å 2 for each 579 stack. The stacks were motion corrected with MotionCor2 41 and binned 2-fold, resulting in 580 a pixel size of 1.087 Å/pixel. Meanwhile, dose weighting was performed 42 . The defocus 581

values were estimated with Gctf 43 . 582

Particles for S in complex with 2G1 were automatically picked using Relion 3.0.6 44-47 from 583 manually selected micrographs. After 2D classification with Relion, good particles were 584

selected and subject to two cycle of heterogeneous refinement without symmetry using 585 cryoSPARC 48 .The good particles were selected and subjected to Non-uniform Refinement 586

(beta) with C1 symmetry, resulting in the 3D reconstruction for the whole structures, which 587

was further subject to 3D auto-refinement and post-processing with Relion. For interface 588 between S protein of SARS-CoV-2 and 2G1, the dataset was subject to focused refinement 589

with adapted mask on each RBD-2G1 sub-complex to improve the map quality. The 590

dataset of similar RBD-2G1 sub-complexes were combined if possible and necessary. The 591

re-extracted dataset was 3D classified with Relion focused on RBD-2G1 sub-complex. 592

Then the good particles were selected and subject to focused refinement with Relion, 593 resulting in the 3D reconstruction of better quality on RBD-2G1 sub-complex. The 594 resolution was estimated with the gold-standard Fourier shell correlation 0.143 criterion 49 595

with high-resolution noise substitution 50 . Refer to Supplementary information, Fig. S6-7  596 and Table S1 for details of data collection and processing. 597

For model building of the complex of S of SARS-CoV-2 with 2G1, the atomic model of the 598 S in complex 4A8 (PDB ID: 7C2L) were used as templates, which were molecular dynamics 599 flexible fitted 51 into the whole cryo-EM map of the complex and the focused-refined cryo-600 EM map of the RBD-2G1 sub-complex, respectively. A Chainsaw 52 model of the 2G1 was 601

first obtained using the 4A8 as a template, which was further manually adjusted based on 602 the focused-refined cryo-EM map of the RBD-2G1 sub-complex with Coot 53 . Each residue 603 was manually checked with the chemical properties taken into consideration during model 604

building. Several segments, whose corresponding densities were invisible, were not 605 modeled. Structural refinement was performed in Phenix 54 with secondary structure and 606 geometry restraints to prevent overfitting. To monitor the potential overfitting, the model 607 was refined against one of the two independent half maps from the gold-standard 3D 608 refinement approach. Then, the refined model was tested against the other map. Statistics 609 associated with data collection, 3D reconstruction and model building were summarized in 610

Supplemental information, Supplementary information, Table S1 . 611 612

Binding to S mutants on cell surface 613

Plasmids encoding full length SARS-CoV-2 S (GenBank ID: QHD43416.1) with one or 614 more mutation sites were carried into HEK-293T cells using lipofectamine 3000 615

(ThermoFisher) according to the manufacturer's instruction. After 48 hours, cells were 616 disassociated from the plates using a Cell Dissociation Buffer (ThermoFisher) followed by 617 washing with PBS. Antibody 2G1 at 10 μg/ml was added into cells for a 30 min incubation. 618

Subsequently, cells were washed and incubated with Alexa Fluor 647 labeled Goat anti-619

Human IgG (ThermoFisher) for 30 mins. After final washing, signals were acquired in flow 620 cytometer (BD) and the binding ability to S mutants were evaluated by mean fluorescent 621 intensity (MFI). against SARS-CoV-2 RBD as measured by ELISA and scores higher than 2 are presented. 702 2G1 is highlighted in red. e, Candidate panning using a WA1/2020 pseudovirus-based 703 screening model. Antibodies were 10-fold serially diluted from 10 1 μg/mL to 10 -4 μg/mL. interaction sites of 2G1 that affects the binding ability of 2G1 to varying degrees .  815  816  817  818  819  820  821  822  823  824  825  826  827  828  829  830  831  832  833  834  835  836  837 838 Fig. S1 Evaluation of binding and neutralization of selected antibody candidates. a-839 b, Candidates' EC50 in the concentration-dependent RBD (a) and S1 (b) binding test using 840

ELISA. Antigens were 3-fold serially diluted from 0.300 μg/mL to 0.0012 μg/mL. S bound with 2G1 versus the overall structure that it is refined against (black); of the model 906 refined against the first half map versus the same map (red); and of the model refined 907 against the first half map versus the second half map (green). The small difference between 908 the red and green curves indicates that the refinement of the atomic coordinates did not 909 suffer from overfitting. g, FSC curve of the refined model of RBD-2G1 sub-complex, which 910

is same to the f. 911 

LiZ conducted experiments on antibody expression, analytical 661 development, and characterization. WX, SZ, TJ, conducted in vitro virus neutralizing 662 assays. YB, BZ coordinate project activities and provided critical discussion

S trimers (b). c, Affinity analysis of 2G1 bound to S trimers of SARS-CoV-2 WA1/2020

Chips fixed with S trimers were loaded on 731

2G1 Fab varied from 1.250 μg/mL to 0.039 μg/mL were injected over 732 the chips for measuring the real-time association and dissociation parameters

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Early introductions and transmission of SARS-CoV-2 variant B.1.1.7 in the United 935 States

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Antibody evasion by the P.1 strain of SARS-CoV-2

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. 941

Viral infection and transmission in a large, well-traced outbreak caused by the SARS-943

CoV-2 Delta variant. medRxiv

SARS-CoV-2 escaped natural immunity, raising questions about 945 vaccines and therapies

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic 947 coronaviruses in mice

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent 951 therapeutic antibody

A neutralizing human antibody binds to the N-terminal domain of the Spike protein 953 of SARS-CoV-2

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and 955 serum antibody neutralization

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-957 derived polyclonal antibodies

Multiple SARS-CoV-2 variants escape neutralization by vaccine-959 induced humoral immunity

Will SARS-CoV-2 variants of concern affect the promise of vaccines?

Evolving biothreat of variant SARS-CoV-2 -molecular 963 properties, virulence and epidemiology

Two-step strategy for the identification of SARS-CoV-2 variant of concern 965 202012/01 and other variants with spike deletion H69-V70

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. 970

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 972 convalescent plasma. bioRxiv

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-976 induced sera

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. 978

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. 982

In vitro data suggest that Indian variant B.1.617 of SARS-CoV-2 escapes 984 neutralization by both receptor affinity and immune evasion

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Genomic analysis reveals a rapid spread and predominance of lambda 989 (C.37) SARS-COV-2 lineage in Peru despite circulation of variants of concern

Characterization of the emerging B.1.621 variant of interest of SARS-992

Emerging SARS-CoV-2 Variants and Impact in Global 994

Vaccination Programs against SARS-CoV-2/COVID-19. Vaccines-Basel 9

SARS-CoV-2 variants, spike mutations and immune escape

Structural basis of a shared antibody response to SARS-CoV-2

Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike 1001 protein

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 1005 variants

The reproductive number of the Delta variant of SARS-CoV-2 is far higher 1007 compared to the ancestral SARS-CoV-2 virus

SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades 1009 antibodies induced by infection and vaccination

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

Automated acquisition of cryo-electron micrographs for single particle 1015 reconstruction on an FEI Tecnai electron microscope

MotionCor2: anisotropic correction of beam-induced motion for improved 1017 cryo-electron microscopy

Measuring the optimal exposure for single particle cryo-EM using a 2.6 angstrom reconstruction of rotavirus VP6

Real-time CTF determination and correction

New tools for automated high-resolution cryo-EM structure determination in 1023 RELION-3

Accelerated Cryo-EM Structure Determination with 1025 Parallelisation using GPUs in Relion-2

RELION: Implementation of a Bayesian approach to cryo-EM structure 1027 determination

A Bayesian View on Cryo-EM Structure Determination

cryoSPARC: algorithms for rapid 1031 unsupervised cryo-EM structure determination

Optimal determination of particle orientation, absolute hand, 1033 and contrast loss in single-particle electron cryomicroscopy

High-resolution noise substitution to measure overfitting and validate 1035 resolution in 3D structure determination by single particle electron cryomicroscopy

Flexible fitting of atomic structures 1038 into electron microscopy maps using molecular dynamics

Overview of the CCP4 suite and current developments

Features and development of Coot

PHENIX: a comprehensive Python-based system for macromolecular 1044 structure solution

We declare that none of the authors have competing financial interests .  668  669  670  671  672  673  674  675  676  677  678  679  680  681  682  683  684  685  686  687  688  689  690  691  692  693  694